BIOCON Bets on Biosimilars, GLP 1 to pay the next stage of growth

Biocon is preparing to expand its biological business sectors, genetic services and research services, with a strategic focus on vital degrees and the emerging GLP-1 treatment sector.

Sidharth Mittal, Managing Director and CEO of Biocon, said, said Biocon, said Biocon. Work today.

Sheds light on the upcoming launches in the United States, Europe and Canada, including Bevacizumab and insulin insulin by the United States of America. Insulin Asbart is the first biological insulin that is the rapid replacement of its approval.

The company launched Yesafili as the first Affriecept in Canada and got a positive opinion from EMA in Europe. The vital Denosumab obtained the approval of both EMA and MHRA, the United Kingdom, while the vital UStekinumab was approved by the UK MHRA.

All of these products will be marketed to move forward. He added: “A mixture of new launch operations and the growing market share of current products continues to build momentum.”

Biocon currently has 10 biological products that have been marketed worldwide and have some approvals, which are good for launch in the future. Beyond biosimilars, biocon sees opportunities to expand the range of insulin portfolio, especially with creators turning to focus on GLP treatments. “This opens the possibility of bringing in our insulin to many patients all over the world. We see supportive trends in insulin works,” Metal pointed out.

In the pharmaceutical sector, Biocon acts as a strategic push to the GLP-1 drugs, including Liraglutide, Smaglutide and Tirzepatide. The company launched Liraglutide in the United Kingdom and the European Union and has recently obtained Liraglutide in India.

Metal said that the deposit files for Simajlotide and Terzopatid are ongoing in selected markets, as they expect launch operations in 2027. Regardless of the GLP-1, the Biocon limestone portfolio, which includes and injecting solid materials, grows throughout the United States and other markets.

“Although the GLP-1 sector is suitable, a few companies have approvals on Liraglutide, and none of them has yet obtained approval of Semaglutide in general,” said Metal. Sheds light on the vertical integration of the Biocon, which covers drugs, drug products, and hardware groups, as a major development.

He added: “We also have a strong commercial infrastructure and cooperate with local partners in markets such as Latin America and the Middle East. In general, we are in a good position to take advantage of opportunities in the GLP-1S for generational drugs.”

He said: “The GLP-1 will be a major contributor to revenue for us. We have a set of 10 GLP-1 products, including the Duar Dubles and Terzopatid. Scientifically, we are confident of receiving approvals from different organizers to this.”

To support these aspirations, the Biocon assigned the GLP-1 facility on the latest model in Bangaluru, which will meet the needs of local markets and export alike and is expected to market in the 27th fiscal year. “Our philosophy is to bring medications to all patients under one quality system,” Metal explained.

This facility will meet the needs of work via bottles, cartridges, pre -filled injectors, and drug group products, which enhances our ability to provide wallet requirements worldwide. “

The company also focuses on spreading strategic capital. It has already invested in GLP-1 drugs and drug products facilities. In the case of insulin, the company has already doubled its ability to drug products in Malaysia and plans to increase the expansion of drug substances over the next few years.

“With these investments, the majority of CAPEX has been completed for the next 2-3 years. We will now focus on Cynanty Capex,” Metal said.

Earlier this year, Biocon 4,500 rupees gathered through QIP, allowing it to meet the obligations of structural investments and increase its share in biotechnology from 72 % to 78 % on a completely diluted basis. In Q1 FY26, Biocon reported revenue of 4,022 crushers, with a biological increase by 18 %, 6 % increase medications, and CRDMO (previous research services) by 11 %.

EBITDA 19 % grew to 829 rupees. The landmarks of the public products of biological products in the quarter included the launch of the Liraglutide in the European Union, as well as the approvals of Dasatinib, Lenalidomide, Micafungin and Everolimus in the United States.

In India, the recent approval of Liraglutide is the first GLP-1 product for the country, which will be marketed through its partners. This quarter, Biocon also obtained the approval of the Food and Drug Administration (FDA) on Rivaroxpan tablets.

In addition, the Brazilian Anvisa surveyed the three API manufacturing sites with zero notes, which increases the promotion of the company’s global production and regulating the organizational footprint.